10.22.20
During the Council for Responsible Nutrition (CRN) virtual conference, “New, Now, Next,” Steven Tave, director of FDA’s Office of Dietary Supplement Programs, identified a number of legislative steps he believes could “bridge a regulatory gap” at points where, for example, the agency’s hands may be tied with respect to enforcement.
Tave characterized this regulatory gap as a barrier to enforcement, leading to a significant amount of non-compliance in the dietary supplements industry compared to other industries under FDA oversight. Still, Tave said, “we have a clear segment of industry participants who we believe are consistently willing to distribute compliant products.”
That there are non-compliant products on the marketplace today “isn’t a matter of FDA not wanting to enforce the law,” he said, but rather, “there are a number of tools identified which would allow us to enforce the law more effectively.”
Barriers to Enforcement
Tave said to remain skeptical of suggestions that FDA wo
Tave characterized this regulatory gap as a barrier to enforcement, leading to a significant amount of non-compliance in the dietary supplements industry compared to other industries under FDA oversight. Still, Tave said, “we have a clear segment of industry participants who we believe are consistently willing to distribute compliant products.”
That there are non-compliant products on the marketplace today “isn’t a matter of FDA not wanting to enforce the law,” he said, but rather, “there are a number of tools identified which would allow us to enforce the law more effectively.”
Barriers to Enforcement
Tave said to remain skeptical of suggestions that FDA wo
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
